

Atg3 (AA6): sc-100508

BACKGROUND

Atg3 (autophagy-related protein 3), also known as APG3-like, hAPG3 or PC3-96, is an E2-like enzyme that localizes to the cytoplasm and is expressed in a variety of tissues with predominant levels found in kidney, placenta, liver, heart and skeletal muscle. Atg3 catalyzes the formation of the Atg8-phosphatidylethanolamine (Atg8-PE) conjugate, a reaction that is essential for autophagy (a cellular process that allows for the degradation of organelles and bulk cellular proteins). The process of forming the Atg8-PE conjugate begins with the removal of the C-terminal arginine residue of Atg8 by Atg4, a cysteine protease. The, now exposed, glycine residue is then activated by Atg7 and is then transferred to Atg3 for the final conjugation to PE. This last step can be accelerated by the presence of the Atg12-Atg5 conjugate which functions similarly to an E3 enzyme.

REFERENCES

1. Tanida, I., et al. 2002. Human Apg3p/Aut1p homologue is an authentic E2 enzyme for multiple substrates, GATE-16, GABARAP, and MAP-LC3, and facilitates the conjugation of hApg12p to hApg5p. *J. Biol. Chem.* 277: 13739-13744.
2. Wu, B.X., et al. 2006. The rat Apg3p/Aut1p homolog is upregulated by ischemic preconditioning in the retina. *Mol. Vis.* 12: 1292-1302.
3. Yamada, Y., et al. 2006. Crystallization and preliminary X-ray analysis of Atg3. *Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.* 62: 1016-1017.
4. Yamada, Y., et al. 2007. The crystal structure of Atg3, an autophagy-related ubiquitin carrier protein (E2) enzyme that mediates Atg8 lipidation. *J. Biol. Chem.* 282: 8036-8043.
5. Hanada, T., et al. 2007. The Atg12-Atg5 conjugate has a novel E3-like activity for protein lipidation in autophagy. *J. Biol. Chem.* 282: 37298-37302.
6. Shao, Y., et al. 2007. Stimulation of Atg12-Atg5 conjugation by ribonucleic acid. *Autophagy* 3: 10-16.
7. Ma, J., et al. 2007. Over-expression of autophagy-related genes inhibits yeast filamentous growth. *Autophagy* 3: 604-609.

CHROMOSOMAL LOCATION

Genetic locus: ATG3 (human) mapping to 3q13.2; Atg3 (mouse) mapping to 16 B5.

SOURCE

Atg3 (AA6) is a mouse monoclonal antibody raised against recombinant Atg3 of human origin.

PRODUCT

Each vial contains 100 µg IgG_{2b} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

Atg3 (AA6) is recommended for detection of Atg3 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)] and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for Atg3 siRNA (h): sc-72582, Atg3 siRNA (m): sc-72583, Atg3 shRNA Plasmid (h): sc-72582-SH, Atg3 shRNA Plasmid (m): sc-72583-SH, Atg3 shRNA (h) Lentiviral Particles: sc-72582-V and Atg3 shRNA (m) Lentiviral Particles: sc-72583-V.


Molecular Weight of Atg3: 42 kDa.

Positive Controls: Jurkat whole cell lysate: sc-2204.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

DATA



Atg3 (AA6): sc-100508. Western blot analysis of Atg3 expression in Jurkat whole cell lysate.

SELECT PRODUCT CITATIONS

1. Wang, H., et al. 2018. miR-16 mimics inhibit TGF-β1-induced epithelial-to-mesenchymal transition via activation of autophagy in non-small cell lung carcinoma cells. *Oncol. Rep.* 39: 247-254.
2. Li, L., et al. 2018. MicroRNA-28 promotes cell proliferation and invasion in gastric cancer via the PTEN/PI3K/AKT signalling pathway. *Mol. Med. Rep.* 17: 4003-4010.
3. Pacheco-Velázquez, S.C., et al. 2018. Energy metabolism drugs block triple negative breast metastatic cancer cell phenotype. *Mol. Pharm.* 15: 2151-2164.

RESEARCH USE

For research use only, not for use in diagnostic procedures.